Spero Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| SPERO THERAPEUTICS, INC. | ||
| Date: March 26, 2026 | By: | /s/ Esther Rajavelu |
|---|---|---|
| Esther Rajavelu | ||
| President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Esther Rajavelu or her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Esther Rajavelu | President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Treasurer, and Director | March 26, 2026 |
| Esther Rajavelu | (Principal Executive, Financial and Accounting Officer) | |
| /s/ Milind Deshpande, Ph.D. | Director | March 26, 2026 |
| Milind Deshpande, Ph.D. | ||
| /s/ Scott Jackson | Director | March 26, 2026 |
| Scott Jackson | ||
| /s/ John C. Pottage, M.D. | Director | March 26, 2026 |
| John C. Pottage, M.D. | ||
| /s/ Cynthia Smith | Director | March 26, 2026 |
| Cynthia Smith | ||
| /s/ Frank E. Thomas | Director | March 26, 2026 |
| Frank E. Thomas | ||
| /s/ Kathleen Tregoning | Director | March 26, 2026 |
| Kathleen Tregoning | ||
| /s/ Patrick Vink, M.D. | Director | March 26, 2026 |
| Patrick Vink, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.